Final results of UK NCRI phase II trial of pembrolizumab and radiotherapy in cutaneous T cell lymphoma

The outlook for patients with advanced cutaneous T-cell lymphomas (CTCL); mycosis fungoides (MF) and Sézary syndrome (SS) remains poor and most systemic treatments provide short-lived remissions. Immunotherapy has provided a major cancer breakthrough, and the PORT trial was designed to investigate the efficacy of Pembrolizumab and whether the addition of Radiotherapy (RT) could further enhance systemic "abscopal" anti-tumour immune responses. Pembrolizumab followed by 12Gy in 3 fractions RT to a localized lesion was investigated in a single-arm, multicentre phase II trial for relapsed/refractory CTCL. Primary endpoint was overall response rate (ORR), secondary endpoints included duration of response (DOR), abscopal response, progression-free survival (PFS), overall survival (OS). 46 patients (41 MF, 5 SS) were registered, median age 63 (24-83), 24% stage IV. Median follow-up was 24.8 months. 24% of patients remained on treatment for >1 year whilst 57% received.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-07-23
DOI
https://doi.org/10.3324/haematol.2025.288878
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Final results of UK NCRI phase II trial of pembrolizumab and radiotherapy in cutaneous T cell lymphoma

N. O’Rourke, Stephen Morris, Eleanor James, Toyin Adedayo et al.
Haematologica
Cutaneous lymphoproliferative disorders research
article

Final results of UK NCRI phase II trial of pembrolizumab and radiotherapy in cutaneous T cell lymphoma

N. O’Rourke, Stephen Morris, Eleanor James, Toyin Adedayo, Nadjet El-Mehidi, Graham Collins, Eve Gallop‐Evans, Eleanor Cheadle, A Bates, William Wilson, Wendy Osborne, James Paterson, Timothy Illidge, Richard Cowan, Sean Whittaker, Julia Scarisbrick, Jeff Ward, Joya Pawade
article en

Abstract

The outlook for patients with advanced cutaneous T-cell lymphomas (CTCL); mycosis fungoides (MF) and Sézary syndrome (SS) remains poor and most systemic treatments provide short-lived remissions. Immunotherapy has provided a major cancer breakthrough, and the PORT trial was designed to investigate the efficacy of Pembrolizumab and whether the addition of Radiotherapy (RT) could further enhance systemic "abscopal" anti-tumour immune responses. Pembrolizumab followed by 12Gy in 3 fractions RT to a localized lesion was investigated in a single-arm, multicentre phase II trial for relapsed/refractory CTCL. Primary endpoint was overall response rate (ORR), secondary endpoints included duration of response (DOR), abscopal response, progression-free survival (PFS), overall survival (OS). 46 patients (41 MF, 5 SS) were registered, median age 63 (24-83), 24% stage IV. Median follow-up was 24.8 months. 24% of patients remained on treatment for >1 year whilst 57% received.

Haematologica
North Bristol NHS Trust (GB), University Hospitals Birmingham NHS Foundation Trust (GB), Nottingham University Hospitals NHS Trust (GB), King's College - North Carolina (US), King's College London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Velindre NHS Trust (GB), Manchester Academic Health Science Centre (GB), NHS Greater Glasgow and Clyde (GB), Newcastle upon Tyne Hospitals NHS Foundation Trust (GB), University Hospital Southampton NHS Foundation Trust (GB), Glasgow Clyde College (GB), Manchester University NHS Foundation Trust (GB), Guy's and St Thomas' Charity (GB), The Christie NHS Foundation Trust (GB), Oxford University Hospitals NHS Trust (GB), CRUK Lung Cancer Centre of Excellence (GB), NIHR Manchester Biomedical Research Centre (GB), University College London (GB)
Amgen, Pfizer, AstraZeneca, Therakos, Helsinn, BeiGene, Cancer Research UK, University College London, Swedish Orphan Biovitrum
No poverty
Openalex Percentile: Top 7%
Cutaneous lymphoproliferative disorders research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.